Yumi Ishikura1, Ayako Maeda-Minami1, Maiko Hosokawa1, Atsuto Onoda2, Yohei Kawano1, Tomomi Ihara3, Masao Sugamata3, Ken Takeda2, Yasunari Mano4. 1. Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan. 2. Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University, Yamaguchi, Japan. 3. Department of Pathology, Tochigi Institute of Clinical Pathology, Tochigi, Japan. 4. Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan; mano@rs.tus.ac.jp.
Abstract
BACKGROUND/AIM: Recent experimental studies have reported that leukotriene receptor antagonists (LTRAs) might protect against dementia. However, few clinical studies have examined this in humans. This study assessed whether the use of LTRAs can prevent the onset of dementia in humans. PATIENTS AND METHODS: A large population-based retrospective cohort study was conducted using a health insurance claims database in Japan, which included patients newly diagnosed with bronchial asthma between 2006 and 2015. Each of these patients that was LTRA user was matched with a randomly selected LTRA non-user according to age, sex, and bronchial asthma diagnostic year. RESULTS: There were 10,471 patients in both the LTRA user and the LTRA non-user group. Using Cox proportional hazards models, a significant reduction in the risk of developing dementia was observed in the LTRA user group compared to the non-user group (adjusted hazard ratio=0.42, 95% confidence interval=0.20-0.87, p=0.019). CONCLUSION: Our data suggest that the use of LTRAs may prevent the onset of dementia in asthmatic patients.
BACKGROUND/AIM: Recent experimental studies have reported that leukotriene receptor antagonists (LTRAs) might protect against dementia. However, few clinical studies have examined this in humans. This study assessed whether the use of LTRAs can prevent the onset of dementia in humans. PATIENTS AND METHODS: A large population-based retrospective cohort study was conducted using a health insurance claims database in Japan, which included patients newly diagnosed with bronchial asthma between 2006 and 2015. Each of these patients that was LTRA user was matched with a randomly selected LTRA non-user according to age, sex, and bronchial asthma diagnostic year. RESULTS: There were 10,471 patients in both the LTRA user and the LTRA non-user group. Using Cox proportional hazards models, a significant reduction in the risk of developing dementia was observed in the LTRA user group compared to the non-user group (adjusted hazard ratio=0.42, 95% confidence interval=0.20-0.87, p=0.019). CONCLUSION: Our data suggest that the use of LTRAs may prevent the onset of dementia in asthmatic patients.
Authors: Y Cha; T Erez; I J Reynolds; D Kumar; J Ross; G Koytiger; R Kusko; B Zeskind; S Risso; E Kagan; S Papapetropoulos; I Grossman; D Laifenfeld Journal: Br J Pharmacol Date: 2017-05-18 Impact factor: 8.739
Authors: Kirsten M Fiest; Nathalie Jetté; Jodie I Roberts; Colleen J Maxwell; Eric E Smith; Sandra E Black; Laura Blaikie; Adrienne Cohen; Lundy Day; Jayna Holroyd-Leduc; Andrew Kirk; Dawn Pearson; Tamara Pringsheim; Andres Venegas-Torres; David B Hogan Journal: Can J Neurol Sci Date: 2016-04 Impact factor: 2.104
Authors: Tim Wilkinson; Amanda Ly; Christian Schnier; Kristiina Rannikmäe; Kathryn Bush; Carol Brayne; Terence J Quinn; Cathie L M Sudlow Journal: Alzheimers Dement Date: 2018-04-03 Impact factor: 21.566
Authors: Julia Marschallinger; Iris Schäffner; Barbara Klein; Renate Gelfert; Francisco J Rivera; Sebastian Illes; Lukas Grassner; Maximilian Janssen; Peter Rotheneichner; Claudia Schmuckermair; Roland Coras; Marta Boccazzi; Mansoor Chishty; Florian B Lagler; Marija Renic; Hans-Christian Bauer; Nicolas Singewald; Ingmar Blümcke; Ulrich Bogdahn; Sebastien Couillard-Despres; D Chichung Lie; Maria P Abbracchio; Ludwig Aigner Journal: Nat Commun Date: 2015-10-27 Impact factor: 14.919